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Background/aim: Autologous transfusion using a cell saver system has been used in liver transplantation with controversial outcomes.
Its efficiency in patients with massive intraoperative transfusion has not been studied yet. This study aimed to evaluate effect of cell
salvage (CS) on intraoperative bleeding and transfusion practices in liver transplantation with massive intraoperative transfusion.
Materials and methods: Consecutive patients aged ≥18 years with intraoperative massive blood transfusion (≥ 6 units) between March
2014 and September 2020 were included. Patients subjected to CS were grouped as CS, whereas other patients were grouped as control.
Number of transfused red blood cells was study’s primary outcome.
Results: There were 38 and 32 patients in CS and control groups, respectively. Median blood loss was significantly lower in CS group
than in control group (2500 mL vs. 4000 mL, p = 0.010). There were significantly more transfusions of red blood cells, fresh frozen
plasma, platelets, and cryoprecipitates in CS group (p < 0.05). Postoperative median hemoglobin levels were determined as 4.8 g/dL and
8.2 g/dL in CS and control groups (p < 0.001). The decrease in postoperative hemoglobin levels compared to preoperative values was
significantly higher in the CS group (p < 0.001). The mortality rate in postoperative first year was significantly higher in CS group than
in control group (36.8% vs. 12.5%, p = 0.041).
Conclusion: Use of CS in patients undergoing liver transplantation with massive intraoperative transfusion did not improve clinical
and transfusion-related outcomes. In conclusion, its usage can be questionable given the absence of any clinical benefit and presence of
poor outcomes.
Key words: Liver transplantation, bleeding, autologous blood transfusion, red blood cell transfusion

1. Introduction
Liver transplantation is a unique treatment modality
indicated for different end-stage liver diseases [1]. It
has a variable intraoperative bleeding potential [2,3].
Coagulopathy due to the underlying chronic liver
diseases and surgical complexity are the major risk
factors for massive bleeding in these patients [2]. The
intraoperative blood loss and blood product requirements
during liver transplantation have considerably decreased
during the course of the last several decades; yet large
volume transfusion of red blood cells (RBC) and blood
products are still required for the management of massive
intraoperative bleeding in 10% to 20% of the cases [3–5].
The patient blood management strategy includes
allogeneic blood transfusions and autologous cell salvage
techniques [2,4]. Each modality has its advantages and
disadvantages as per the outcomes of liver transplantation.

Massive transfusion has been found to be associated with
decreased patient and graft survival rates [1,6] and with an
increased risk of transfusion-related complications such as
profound coagulopathy, acute lung injury, and acute kidney
injury [5]. The limited blood products and exposure to viral,
bacterial, and protozoal diseases are the primary concerns
disfavoring allogeneic blood transfusions [1]. Autologous
transfusion using a cell saver system is another technique
used to manage bleeding during major surgical procedures
such as liver transplantation, coronary artery bypass
grafting, and other types of operations with significant
bleeding risk [1,7–10]. Some reports revealed that higher
blood losses might be seen during liver transplantation
due to fibrinolysis developed in association with cell
salvage (CS) [11,12]. The cost of the technique is another
primary concern preventing its widespread use [1,3,13].
Although its use has been associated with reducing
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blood transfusion, its impact on the early and long-term
outcomes is unclear [1,3,5,7,14]. Despite the data available
on the use of CS in liver transplantation in the literature, to
date, there is no study in which the beneﬁt and reliability
of CS were evaluated in patients requiring massive blood
transfusion. Additionally, the relationship between the
coagulative and fibrinolytic laboratory parameters and CS
has also not been studied in detail.
In view of the foregoing, the objective of this study is
to evaluate the effect of the administration of autologous
transfusion using a cell saver system on the amount of
intraoperative bleeding, transfusion practices, laboratory
investigations for bleeding disorders, and on the
outcomes in liver transplantation patients with massive
intraoperative transfusion.
2. Materials and method
2.1. Study design
The patients who underwent liver transplantation between
March 2014 and September 2020 in İstanbul Medipol
University Hospital were retrospectively evaluated.
The institutional ethics committee approved the study
(approval number: 2020/975). The study was carried out
in accordance with the principles of the Declaration of
Helsinki.

2.2. Population and sample
The population of the study comprised all consecutive
patients who required massive intraoperative transfusion
(≥6 transfusions of RBC units) [15]. The exclusion criteria
were determined as having an age <18 years, incomplete
data, deceased donor transplantation and congenital
bleeding disorders. The patients who met the study inclusion
criteria were divided into two groups; the group of patients
with intraoperative CS, that is, the CS group, and the group
of patients without CS, that is, the control group (Figure).
2.3. Anesthesia protocol and surgical technique
The monitoring and anesthesia protocol used in this study
was previously described in the literature [13–16]. For the
surgical approach, hepatectomy preserving the recipient’s
inferior vena cava was undertaken using the piggy-back
technique (the classic technique).
Blood analysis
Serial arterial blood gas analysis included hemoglobin,
potassium, and ionized calcium measurements. Intraoperative
measurements of INR (international normalized ratio) and
platelet count were used to monitor the coagulation profile
of the patients. The decision to carry out a transfusion
during the surgery was made jointly by the surgeon and the
anesthesiologist based on the patient’s hemodynamic status,
blood loss, and hemoglobin concentration [7]. Accordingly,

Figure. Flow chart of research methodology.
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in cases where deemed necessary, the Rapid Infuser System
(Belmont Instrument Corp., Billerica, MA) was used to
administer the blood product.
Crystalloid and colloid solutions were used
intravenously to make up for the volume loss. If a patient
received a transfusion, the tests with abnormal results were
repeated and dealt with in accordance with the algorithm
while the patient was in the operating room and later on in
the intensive care unit.
In the event that the patient’s hemoglobin (Hb)
level was found to be below 8 g/dL, an allogeneic red
blood cell (RBC) transfusion was performed. In the CS
group, allogeneic RBC was performed if the Hb level
did not rise above 8 g/dL despite the retransfusion of
all autologous blood. For Hb levels of 8 to 10 mg/L, the
transfusion decision was made based on symptoms and
signs of anemia. If bleeding persisted, the allogeneic fresh
frozen plasma (FFP), platelet, and antifibrinolytic agent
(tranexamic acid) transfusion were used in accordance
with the thromboelastography guidance [14]. A kaolinactivated thromboelastography assay was performed
using a 5000 series analyzer (Haemoscope, Inc, Niles,
Illinois).
2.4. Cell saver technique
The cell saver system was not used in liver transplant
patients with malignancy [1]. The Cell Saver (Haemonetics,
Braintree, MA, USA) machine was prepared with a twosuction system before the surgery. As the standard protocol,
heparinized saline solution with 5000 IU of heparin in 1
L of 0.9% saline solution was used at a rate of 100 mL/h
to prevent thrombogenesis during blood collection. If the
measured intraoperative hemoglobin level was 8 g/dL or
lower, the processed (filtrated, centrifuged, washed, and
concentrated) blood was retransfused. The blood may
contain about 0.002% of the prewash heparin.
2.5. Variables
The research data were collected from the hospital
information system and the patients’ medical records.
The patients’ demographic [age, gender, height, weight,
body mass index (BMI)], clinical (smoking history,
comorbidities, the Child-Turcotte-Pugh category, the
Model for End-stage Liver Disease (MELD) score and
subgroups, reasons for transplantation), laboratory,
operative, and follow-up data were recorded.
The Child-Turcotte-Pugh scores were calculated for
all patients and categorized from A to C [15]. The MELD
score was calculated using the immediate preoperative
values for INR, serum creatinine, total bilirubin, and
primary etiology of liver failure [16,17].
In the control group, intraoperative blood loss was
calculated by the addition of the blood volume in the
suction container to the volume of blood collected with
abdominal sponges and compresses. On the other hand,

in the CS group, intraoperative blood loss was calculated
by the addition of the blood volume in the cell saver
system to the blood loss calculated for the control group.
The total intraoperatively transfused RBC, FFP, platelet,
cryoprecipitate, and albumin values were recorded. The
allogeneic RBC volume was 300 mL per unit. Each 300
mL of autologous blood retransfused in the CS group was
recorded as 1 unit.
2.6. Follow-up
Postoperatively, patients were followed in the intensive
care unit and extubated based on the results of the blood
gas analysis, laboratory tests, and Doppler sonography.
The patients were kept in the intensive care unit until
they were hemodynamically stable and had good graft
function. They were discharged from the hospital after it
was established that they were clinically well.
The overall mortality rate was determined at the end of
the postoperative third month and the first year. The followup data available in the hospital medical records were
analyzed. Patients whose follow-up data were missing were
given a call-in order to determine the overall mortality rates.
2.7. Statistical analysis
The number of transfused RBC and blood product units
was the study’s primary outcome. The secondary outcomes
were the changes in the laboratory results associated with
the bleeding disorders and the mortality rates at the
postoperative third month and the first year.
Descriptive statistics were expressed as mean ±
standard deviation or median and minimum-maximum
values in the case of continuous variables depending
on the distribution pattern of the respective statistic.
Categorical variables were expressed as numbers and
percentage values. The conformity of the numerical
variables with normal distribution was analyzed using
the Shapiro-Wilk, Kolmogorov-Smirnov, and AndersonDarling tests. The Independent Samples t-test was
used to compare two independent groups in the case of
numerical variables, which were determined to conform
to normal distribution. The Mann-Whitney U test was
used to compare two independent groups in the case of
variables that were determined not to conform to normal
distribution. Pearson’s chi-squared and Fisher’s exact tests
were used to compare the differences between categorical
variables in 2 × 2 tables. The Fisher-Freeman-Halton test
was used in RxC tables. The Wilcoxon signed-rank test
was used to compare the differences of the laboratory
parameters in two different intervals.
For statistical analysis, Jamovi project (2021) (Jamovi
version 2.2.2.0) [computer software, retrieved from https://
www.jamovi.org) and JASP 0.16 (JASP version 0.16;
retrieved from https://jasp-stats.org) software packages
were used. In all statistical analyses, the significance level
(p-value) was set at 0.05.
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3. Results
Seventy patients with massive intraoperative transfusion who
met the study inclusion criteria were included in the study.
CS was used in 38 (54.3%) of these patients. The groups
were similar in the demographic and clinical characteristics
except for the incidence of hypertension (p = 0.033) and

the distribution of the preoperative diagnoses (p = 0.017).
A significantly higher number of patients in the CS group
had the transplantation due to HCV (Hepatitis C virus) and
cryptogenic causes. The median value of the MELD score
was similar in both groups (p = 0.140). The demographic and
clinical characteristics of the patients are given in Table 1.

Table 1. Demographic and clinical characteristics of the study groups.
Overall
(n = 70)

Control group
(n = 32)

Group CS
(n = 38)

p

53.7 ± 11.1

54.1 ± 11.7

53.3 ± 10.6

0.658***

55.0 [24.0–72.0]

55.5 [28.0–72.0]

55.0 [24.0–71.0]

Male

48 (68.6)

23 (71.9)

25 (65.8)

Female

22 (31.4)

9 (28.1)

13 (34.2)

Height (cm) †

165.3 ± 9.4

165.8 ± 9.5

164.8 ± 9.4

0.691**

Weight (kg)

Age (year) †, ‡
Sex §

0.773*

75.2 ± 14.5

72.3 ± 13.7

77.5 ± 14.9

0.135**

Body mass index (kg/m2) †

27.5 ± 5.3

26.5 ± 5.1

28.3 ± 5.5

0.169**

Smoking history

25 (36.2)

11 (34.4)

14 (37.8)

0.962*

41 (58.6)

21 (65.6)

20 (52.6)

0.392*

Diabetes mellitus

30 (42.9)

14 (43.8)

16 (42.1)

0.999*

Hypertension

15 (21.4)

11 (34.4)

4 (10.5)

0.033*

Coronary artery disease

16 (22.9)

10 (31.2)

6 (15.8)

0.212*

Chronic renal failure

5 (7.1)

3 (9.4)

2 (5.3)

0.654*

A

4 (5.7)

2 (6.2)

2 (5.3)

B

32 (45.7)

10 (31.2)

22 (57.9)

34 (48.6)

20 (62.5)

14 (36.8)

17.5 [8.0–40.0]

20.0 [11.0–27.0]

16.0 [8.0–40.0]

Hepatitis B

9 (12.9)

3 (9.4)

6 (15.8)

Hepatitis B + hepatitis D

4 (5.7)

2 (6.2)

2 (5.3)

Hepatitis C

8 (11.4)

2 (6.2)

6 (15.8)

Alcoholic cirrhosis

8 (11.4)

5 (15.6)

3 (7.9)

Nonalcoholic steatohepatitis

7 (10.0) a

7 (21.9) b

0 (0.0)

Cryptogenic

21 (30.0)

6 (18.8)

15 (39.5)

Autoimmune

2 (2.9)

1 (3.1)

1 (2.6)

Primary biliary sclerosis

2 (2.9)

0 (0.0)

2 (5.3)

Others

9 (12.9)

6 (18.8)

3 (7.9)

†

§

Comorbidities §
Type of comorbidity

Child score

§

§

C
MELD score

‡

0.058*

0.140***

Reasons for transplantation §

: mean ± standard deviation, ‡: median [min-max], §: n (%)
CS: cell salvage, MELD: Model for end-stage liver disease.
*. Pearson chi-square, Fisher’s exact or Fisher Freeman Halton tests
**. Independent samples t-test
***. Mann-Whitney U test
†
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There were significant differences between the CS
and control groups in terms of preoperative laboratory
test results (Table 2). The median hemoglobin level was
significantly higher in the CS group than in the control
group (10.9 g/dL vs. 8.7 g/dL, p < 0.001). In the CS
group, the prothrombin time and aPTT (activated partial
thromboplastin time) were significantly lower than those
of the control group (p = 0.020 and p = 0.023; respectively).
Other preoperative measurements were similar between
the groups (p > 0.05).
The intra- and intergroup comparisons of the
postoperative laboratory investigations are detailed
in Table 2. There were significant differences in the
laboratory measurements between the preoperative and
postoperative values within each group and between the
postoperative values of the two groups. The postoperative
median hemoglobin levels were 8.2 g/dL and 4.8 g/dL in
the control and CS groups, respectively (p < 0.001). The
postoperative prothrombin time was significantly lower
in the CS group than in the control group (22 s vs. 28.4
s; p = 0.001). The changes between the preoperative and
postoperative laboratory values within each group are
given in Table 2.
The perioperative characteristics of the study groups
are shown in Table 3. There was no difference between
the groups in duration of the surgery, anhepatic phase,
and warm ischemia; however, the cold ischemia time was
significantly lower in Group CS (p = 0.001). A significantly
higher number of patients in the CS group required a
high-dose vasopressor (p = 0.010). The median lactate
level was significantly higher in the CS group than in
the control group (8.4 vs. 4.4 mmol/L, p < 0.001). There
was no significant difference between the groups in the
total volume of the infused intravenous fluid (p = 0.073).
However, the crystalloid fluid volume used in the CS
group was significantly lower than that of the control
group (6000 mL vs. 7250 mL, p = 0.034). The median
blood loss was 4000 mL in the control group. Additionally,
the intraoperative blood loss was significantly lower in the
CS group than in the control group (2500 mL, p = 0.010).
The median values of the transfused allogeneic RBC
were eight and three units in the control and CS groups,
respectively, and significantly higher in the control group
(p < 0.001). The median amount of total RBC, including
the units salvaged for autologous transfusion and the
transfused allogeneic RBC, was 12.6 units. The transfused
total RBC and FFP were significantly higher in Group CS
than in the control group (p < 0.001 in both cases) (Table
4). The distribution of other transfused blood products is
shown in Table 4.
The percentage changes between the postoperative
and preoperative laboratory values within each group are
given in Table 5. There was a significant difference between

the groups in the percentage change in hemoglobin levels
(p < 0.001). The decrease observed in the postoperative
hemoglobin levels compared to the preoperative values
was significantly higher in the CS group than in the control
group.
The length of hospital stay was significantly lower in
the CS group (p = 0.021). The mortality rate in the thirdmonth follow-up was comparable between the groups (p
= 0.314), yet there were more mortalities in the CS group
than in the control group in the first year (36.8% vs. 12.5%,
p = 0.041) (Table 6).
4. Discussion
The findings of this study did not support the use of
CS during liver transplantation since there was no
improvement in the clinical outcomes and the laboratory
parameters related to bleeding disorders. Although the
amount of allogeneic blood transfusion was significantly
decreased, there was a higher number of transfused
blood products, including both the allogeneic and
salvaged blood, in the CS group. In contradiction with the
significantly lower blood loss in the CS group, the total
transfused RBC units were significantly higher, and the
postoperative hemoglobin levels were significantly lower
in the CS group. Based on the study findings, CS usage
was deemed questionable given the absence of any clinical
benefit and the presence of possible adverse effects.
The amount of intraoperative blood loss in liver
transplantation has been regarded as a prognostic factor
affecting the survival and retransplantation rates via
unknown mechanisms [2,4]. A cut-off value of >6 units or
>1100 mL blood transfusion has been associated with the
worse short-term and long-term outcomes [5,15,18,19].
These problematic issues have raised questions about
the indications and amount of blood and blood product
transfusions. Different cut-off values were used in the
previous studies for the number of transfused blood
products and the intervals to define massive blood
transfusion in liver transplantation. The transfusion of
at least four [20], six [15,16,21] or ten units [5,22–25] of
RBC in the intraoperative period [15,20,22–24] or up to
the postoperative 24 h [16,21,25] to 48 h [5] were regarded
as the criteria as per this definition. The transfusion of 6
or more RBC units was accepted as the cut-off value for
the definition of massive intraoperative transfusion [15].
The differences in the amount and the interval may lead to
controversial outcomes.
In order to avoid unnecessary allogeneic blood
transfusions and minimize the amounts thereof during
major surgical procedures, reinfusion of blood collected
in the surgical field has been developed since 1885 [2]. The
reduction in the need for allogeneic transfusions is directly
related to a decrease in the cost and the rate of adverse
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Table 2. Comparison of the preoperative and postoperative laboratory investigations between the groups.
Control group
(n = 32)

Group CS
(n = 38)

p*

Preoperative

8.7 [7.2–13.0]

10.9 [7.8–14.9]

<0.001

Postoperative

8.2 [6.9–10.0]

4.8 [1.5–13.3]

<0.001

p**

0.027

<0.001

Preoperative

73.5 [14.0–390.0]

79.5 [27.0–180.0]

0.728

Postoperative

48.0 [21.0–270.0]

52.5 [17.0–113.0]

0.841

p**

<0.001

<0.001

Preoperative

21.6 [14.2–41.2]

18.0 [12.6–38.0]

0.020

Postoperative

28.4 [18.7–46.9]

22.0 [16.8–40.0]

0.001

p**

<0.001

0.002

Preoperative

1.6 [1.1–3.1]

1.5 [1.0–5.6]

0.750

Postoperative

2.3 [1.5–3.5]

2.2 [1.3–3.4]

0.283

p**

<0.001

<0.001

Preoperative

40.0 [26.0–67.6]

37.0 [24.5–59.0]

0.023

Postoperative

42.0 [33.0–68.3]

39.6 [32.0–107.0]

0.313

p**

0.039

0.002

Preoperative

184.5 [101.0–580.0]

246.5 [84.0–468.0]

0.135

Postoperative

110.5 [64.0–201.0]

110.0 [50.0–250.0]

0.919

p**

<0.001

<0.001

Preoperative

0.9 [0.3–2.9]

0.9 [0.4–4.3]

0.786

Postoperative

0.9 [0.3–2.4]

1.2 [0.5–3.4]

0.002

p**

0.252

0.004

Preoperative

82.8 [23.0–222.4]

87.3 [14.1–264.3]

0.846

Postoperative

77.0 [27.0–222.4]

61.4 [17.6–124.2]

0.006

p**

0.094

<0.001

Preoperative

2.2 [0.2–21.4]

2.1 [0.4–33.0]

0.641

Postoperative

5.0 [2.2–15.0]

6.6 [2.1–20.0]

0.021

p**

0.308

0.001

Preoperative

1.4 [0.1–19.1]

1.2 [0.1–29.0]

0.827

Postoperative

2.5 [0.7–10.5]

2.7 [0.4–11.0]

0.308

p**

0.911

0.087

Hemoglobin (g/dL) ‡

Platelet count (x 103/µL) ‡

Prothrombin time (s) ‡

INR ‡

APTT (s) ‡

Fibrinogen (mg/dL) ‡

Creatine (mg/dL) ‡

GFR (mL/dk/1.73 m2) ‡

Total bilirubin (mg/dL) ‡

Direct bilirubin (mg/dL)*
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Table 2. (Continued).
AST (U/L) ‡
Preoperative

41.8 [14.8–373.0]

50.0 [23.0–2625.0]

0.030

Postoperative

144.8 [86.0–1137.0]

343.5 [109.0–2251.0]

<0.001

p**

<0.001

<0.001

Preoperative

21.5 [5.0–263.0]

30.5 [14.0–2612.0]

0.044

Postoperative

128.4 [70.0–959.0]

374.0 [53.0–1852.0]

<0.001

p**

<0.001

<0.001

Preoperative

3.0 [2.0–4.3]

2.9 [2.2–5.4]

0.855

Postoperative

3.4 [2.8–4.3]

3.1 [1.5–3.8]

0.001

p**

0.002

0.612

ALT (U/L) ‡

Albumin (mg/dL) ‡

: median [min-max]
CS: cell salvage, INR: international normalized ratio, aPTT: activated partial thromboplastin time, GFR: glomerular filtration rate, ALT:
alanine aminotransferase, AST: aspartate aminotransferase
*. Mann-Whitney U test
**. Wilcoxon test
‡

Table 3. Perioperative characteristics of the study groups.

Graft weight/recipient weight ‡
Operative time (min) ‡
Duration of anhepatic phase (min) ‡
Cold ischemia time (min) ‡
Warm ischemia time (min) ‡
Need for vasopressors
Low dose
High dose
CVP-preoperative (cmH2O) †
CVP-postoperative (cmH2O) †
Lactate (mmol/L) intraoperative ‡
postoperative ‡
Total intravenous fluid (mL) ‡
Crystalloids (mL) ‡
Colloids (mL) ‡
Ascites volume (mL) ‡
Total blood loss (mL) ‡
Urine volume (mL) ‡

Control group
(n = 32)

Group CS
(n = 38)

1.3 [0.8–2.0]
540.0 [390.0– 807.0]
74.5 [38.0–370.0]
36.0 [15.0–116.0]
47.5 [17.0–136.0]
30 (93.8)
10 (33.3)
20 (66.7)
11.4 ± 4.6
7.7 ± 2.4
1.1 [0.4–2.9]
4.4 [2.2–12.0]
12,360.0 [5810.0– 20,400.0]
7250.0 [3000.0– 16,000.0]
500.0 [500.0– 1100.0]
2750.0 [1000.0– 9700.0]
4000.0 [1500.0– 8000.0]
2150.0 [450.0– 9000.0]

1.2 [0.6–2.0]
480.0 [360.0– 840.0]
59.5 [35.0– 310.0]
22.0 [10.0– 55.0]
41.0 [25.0– 107.0]
36 (94.7)
2 (5.6)
34 (94.4)
11.1 ± 2.9
7.1 ± 3.1
1.2 [0.6–2.0]
8.4 [3.6–13.0]
14470.0 [7080.0–28,400.0]
6000.0 [3000.0 –20,000.0]
500.0 [500.0– 2000.0]
2250.0 [1000.0 –10,000.0]
2500.0 [1350.0 –18,000.0]
1800.0 [400.0– 4500.0]

p
0.829***
0.151***
0.184***
0.001***
0.107***
0.999*
0.010*
0.762**
0.327**
0.953***
<0.001***
0.073***
0.034***
0.511***
0.387***
0.010***
0.051***

: mean ± standard deviation, ‡: median [min-max], §: n (%)
CS: cell salvage, CVP: central venous pressure
*. Pearson chi-square or Fisher’s exact test
**. Independent samples t-test
***. Mann-Whitney U test
†
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Table 4. Comparison of the intraoperative transfusion practices in the groups.
Control group
(n = 32)

Group CS
(n = 38)

p

Allogeneic red blood cell (unit) ‡

8.0 [6.0–12.0]

3.0 [0.0–21.0]

<0.001***

Total red blood cell (unit)

Number per patient

8.0 [6.0–12.0]

12.6 [6.1–72.0]

<0.001***

Fresh frozen plasma transfusion (unit) ‡

5.0 [0.0–12.0]

13.0 [5.0–32.0]

<0.001***

Thrombocyte transfusion (unit)

0.0 [0.0–4.0]

1.0 [0.0–6.0]

0.025***

2.0 [0.0–12.0]

0.0 [0.0–6.0]

0.004***

7.0 [3.0–15.0]

4.0 [0.0–6.0]

<0.001***

‡

‡

Cryoprecipitate transfusion (unit)

‡

Albumin (20%–100 mL) replacement ‡
: median [min-max]
CS: cell salvage
*. Pearson chi-square or Fisher’s exact test
**. Independent samples t-test
***. Mann-Whitney U test
‡

Table 5. Percent changes between the postoperative and preoperative laboratory parameters in the study groups.
Δ%

Control group
(n = 32)

Group CS
(n = 38)

p

Hemoglobin ‡

–7.8 [–30.4–29.9]

–55.0 [–81.2–50.0]

<0.001

Platelet count ‡

–28.9 [–83.7–192.9]

–35.0 [–78.3–62.3]

0.383

34.8 [–28.2–208.6]

22.0 [–42.9–100.0]

0.294

40.8 [–29.0–219.8]

41.5 [–69.6–130.6]

0.976

9.0 [–39.9–71.2]

8.9 [–20.0–178.4]

0.349

–43.0 [-88.3–14.3]

–54.6 [–74.5–31.0]

0.194

Prothrombin time

‡

INR ‡
APTT

‡

Fibrinogen ‡

: median [min-max]
CS: cell salvage, INR: international normalized ratio, aPTT: activated partial thromboplastin time.
*. Mann-Whitney U test
‡

Table 6. Postoperative outcomes of the study groups.
Control group
(n = 32)

Group CS
(n = 38)

p

18.5 [7.0–90.0]

14.0 [1.0–58.0]

0.021***

3.0 [1.0–20.0]

2.5 [1.0–21.0]

0.369***

Survived

29 (90.6)

30 (78.9)

0.314*

Nonsurvived

3 (9.4)

8 (21.1)

Survived

28 (87.5)

24 (63.2)

Nonsurvived

4 (12.5)

14 (36.8)

Length of hospital stay (day) ‡
Length of intensive care unit (day)

‡

3rd month follow-up §

12th month follow-up §

: median [min-max], §: n (%)
CS: cell salvage
*. Pearson chi-square, Fisher’s exact or Fisher Freeman Halton tests
**. Independent samples t-test
***. Mann-Whitney U test
‡
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effects of the transfusion. It has also been speculated that
the rate of surgical infections, the length of hospital stay,
and the treatment-related costs would decrease [26].
Hence, there is a need to determine the indications and
benefits of the CS approaches in liver transplantation [25].
The use of the CS approaches has been analyzed in
previous studies. Similar to the results of other studies, a
reduction in allogeneic heterologous blood transfusions
was observed in this study in liver transplants [1,3,13,19].
Kırnap et al. demonstrated considerable reductions in the
allogeneic blood transfusions during liver transplantation
[1]. They reported that CS decreased the need for blood
transfusions from 20–25 mL/kg to 5–10 mL/kg yet with
no changes in the transfusion rate, including both the
allogeneic and salvaged transfusions [1]. In Massicotte’s
study, the mean number of transfused allogeneic RBC units
was found as 0.4 per patient regardless of the use of the
CS [3]. Substantial reductions in fresh frozen plasma and
platelet transfusions were reported with the use of CS in
other studies, contrary to the findings of this study [13,19].
In this study, the use of CS was associated with a higher
number of transfused blood and other blood products.
The median transfused RBC units were determined as
8 and 12.6 in the control and CS groups, respectively.
The fact that only patients with massive intraoperative
transfusion ( ≥6 units) were included in this study was the
most significant difference of this study that separated it
from other studies [1,3,13,19].
Due to the lack of clotting factors and platelet on the
washed RBC, an increased blood loss and the requirement
for blood products may occur [25]. The increased rates of
acute kidney injury secondary to the increased hemolysis
and the salvaged blood syndrome and the cost of the
CS system are the other disadvantages. Massicotte et al.
reported an increased blood loss with the use of CS, which
they attributed to two new junior surgeons and speculated
that two RBC unit transfusions could be saved using CS
[3]. Hendriks et al. reported a significantly higher number
of RBC transfusions in patients who underwent liver
transplantation with the use of CS [11]. They concluded
that the use of autologous blood was a poor prognostic
factor for the transfusion requirements. In earlier studies,
more RBC, fresh frozen plasma, cryoprecipitate, and
platelets transfusions were needed in patients who were
administered autologous transfusion using CS [27,28],
which was attributed to hyperfibrinolysis developed
secondary to the release of fibrinolytic compounds from
blood cells in the collected blood and the transplanted
liver [11].

In comparison, in this study, more transfusions
were performed in the CS group, albeit the blood loss
was significantly lower. The rate of the intraoperative
high-dose vasopressor treatment was also higher. The
postoperative hemoglobin level was significantly lower,
along with the use of more transfusions. Given the study’s
retrospective nature, it has proven difficult to analyze the
cause-and-effect relationships between the use of CS and
higher requirement for RBC transfusions. The increased
mortality rate in the postoperative first year needs to be
explained in detail since the use of CS alone does not
explain the relevant finding. Therefore, further prospective
studies are needed to clarify the results of this study.
There were also some limitations to this study. The
primary limitations were the retrospective design, small
sample size, lack of match-pair analysis, absence of fibrin
degradation products, absence of emergency and elective
transplantation data. Additionally, there was difficulty in
analyzing the reciprocal relations between the CS system
and intraoperative bleeding. Lastly, there might have
been a selection bias considering the differences in the
preoperative hemoglobin levels between the groups.
In conclusion, the findings of this study revealed that
the CS approach caused significant reductions in the
number of allogeneic blood transfusions. Nevertheless,
other transfusion-related parameters were poor in patients
with CS. Therefore, the use of CS in patients undergoing
liver transplantation with intraoperative massive blood
transfusion should be reevaluated since it does not seem to
improve the clinical outcomes or the transfusion practices.
Prospective, randomized, large-scale studies are needed
on groups with similar demographic data and longer
follow-up periods.
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